No Panacea for Merck?
New CEO Richard Clark draws few cheers on the Street, where he is seen as unlikely to administer the sort of tough medicine that many think the drugmaker needs
By Amy Barrett
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.